Business context and reporting period
Galena Biopharma, Inc. (the company named in the filing; the request metadata identifies SELLAS Life Sciences Group, Inc.) filed this unaudited Form 10-Q for the quarter ended March 31, 2014. Galena was commercializing Abstral, its first product, while developing oncology candidates NeuVax and GALE-301 and, after a January acquisition, GALE-401.
Financial results and position
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Net revenue | $2.173 million | $0; Abstral launched in 2013 |
| Cost of revenue and acquired-intangible amortization | $0.422 million total | $0 |
| Research and development | $6.770 million | $5.081 million; up 33% |
| Selling, general and administrative | $6.830 million | $1.530 million; up 346% |
| Operating loss | $11.849 million | $6.611 million |
| Net loss | $2.536 million | $9.293 million |
| Cash used in operating activities | $8.048 million | $5.331 million |
| Cash and cash equivalents | $52.427 million at March 31 | $47.787 million at December 31, 2013 |
| Total debt | $9.985 million, including current and long-term portions | $9.892 million at December 31, 2013 |
Reported gross margin was approximately 81% after acquired-intangible amortization, or approximately 85% excluding that amortization. The net loss improved year over year largely because a $9.792 million non-cash gain from a decrease in the fair value of cash-settleable warrants more than offset the operating loss; the prior-year period included a $5.003 million warrant fair-value expense. The 2013 period also included a $2.762 million tax benefit. These items make net loss less indicative of operating performance.
Cash increased by $4.640 million, principally from $10.611 million of warrant-exercise proceeds and $4.059 million of option-exercise proceeds, offset by operating cash use and the $2.010 million GALE-401 acquisition payment. Stockholders’ equity rose to $46.504 million from $5.886 million, in part reflecting warrant and option exercises. The company reported a $12.365 million warrant liability and $6.987 million of contingent purchase-price consideration. The Oxford loan bears 8.45% interest, with 12 months of interest-only payments followed by 30 months of principal and interest; maturity is November 2016.
Material changes, outlook and commentary
- Abstral generated its first reported quarterly revenue. Management expected 2014 Abstral net revenue of approximately $11 million to $15 million, while cautioning there was no assurance it would meet that estimate. Sales were concentrated: three customers accounted for 51%, 15% and 12% of quarterly revenue.
- R&D spending rose mainly from enrollment in the Phase 3 PRESENT NeuVax trial; management expected PRESENT costs to decline in the second half of 2014 as enrollment finished, potentially offset by GALE-401 and Abstral Registry trial costs.
- SG&A increased with the Abstral sales force, marketing team and commercial launch. The company expected continued operating losses and stated it needed significant revenue to become profitable. Management believed working capital would fund operations for more than one year, but warned additional financing might be unavailable on acceptable terms.
- GALE-401 was acquired for $2 million and was expected to enter Phase 2 in 2014. The former owners could receive up to 4 million shares on regulatory milestones and $3 million upon FDA approval; additional license milestones and royalties may apply.
- On April 28, 2014, the company announced a NeuVax HER2 3+ Phase 2 trial with estimated cost of $3 million, expected to be jointly funded by $1.25 million in Department of Defense grant funding and approximately $1.75 million from Galena.
- Key risks include clinical and regulatory uncertainty, Abstral commercialization and revenue execution, dependence on financing, customer concentration, and exposure to cash balances above federally insured limits. The company also disclosed foreign-exchange exposure and said it did not hedge it.
- Shareholder derivative and securities class-action cases and stockholder books-and-records demands were pending; the company also disclosed an SEC investigation concerning matters involving the company and an outside investor-relations firm. It said it was cooperating and intended to defend the matters. No material litigation liability was recorded; potential losses could not be estimated.
Most important facts to verify
- Confirm the issuer identity: this filing is for Galena Biopharma, Inc., not SELLAS Life Sciences Group, Inc.
- Check Abstral’s subsequent sales against the $11 million–$15 million 2014 outlook and assess customer concentration and gross-to-net deductions.
- Assess cash burn, financing needs, debt repayment terms and dilution from outstanding warrants, options and potential GALE-401 milestone shares.
- Track NeuVax and GALE-301/GALE-401 trial enrollment, results, costs and regulatory progress against management’s stated plans.
- Monitor developments in the SEC investigation and litigation, including potential costs or outcomes not estimable at filing.